Taro Pharmaceutical Industries Ltd. has received approval from the Food and Drug Administration for Topicort Topical Spray 0.25%.


Taro Pharmaceutical Industries, Topicort Topical Spray, desoximetasone, corticosteroid, psoriasis


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Taro cleared to market Topicort spray

April 15th, 2013

Taro Pharmaceutical Industries Ltd. has received approval from the Food and Drug Administration for Topicort Topical Spray 0.25%.

The company said Friday that the Topicort (desoximetasone) spray, a corticosteroid, is indicated for the treatment of plaque psoriasis in patients age 18 and older.

In the United States, the corticosteroid spray market has estimated annual sales of $100 million, according to Taro.

Advertisement